Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482636 | 1.00 | L3MBTL1 (0.64) | L3MBTL1TP53ALDH1A1NPSR1TRPV4 | |
| SCHEMBL5559496 | 0.85 | L3MBTL1 (0.49) | L3MBTL1TP53ALDH1A1NPSR1TRPV4 | |
| SCHEMBL74997 | 0.85 | TRPV4 (0.68) | L3MBTL1TP53ALDH1A1TRPV4GAA | |
| SCHEMBL29482639 | 0.85 | TRPV4 (0.68) | L3MBTL1TP53ALDH1A1TRPV4GAA | |
| SCHEMBL15220366 | 0.83 | ALPL (0.51) | L3MBTL1TP53TRPV4KMT2ASMN1; SMN2 | |
| SCHEMBL5984215 | 0.83 | KDM4E (0.52) | L3MBTL1TRPV4KMT2ASMN1; SMN2GAA | |
| SCHEMBL1611864 | 0.83 | L3MBTL1 (0.46) | L3MBTL1TP53ALDH1A1NPSR1TRPV4 | |
| SCHEMBL17392336 | 0.83 | MEN1 (0.60) | L3MBTL1ALDH1A1TRPV4KMT2ASMN1; SMN2 | |
| SCHEMBL29652438 | 0.83 | MEN1 (0.60) | L3MBTL1ALDH1A1TRPV4KMT2ASMN1; SMN2 | |
| SCHEMBL5960683 | 0.82 | SMN1; SMN2 (0.67) | L3MBTL1TP53ALDH1A1NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| WO-2025100970-A1 | TNAP INHIBITORY COMPOUND AND USE THEREOF | 주식회사 레드엔비아 | 2025-05-15 | — | — | WO | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| WO-2025075722-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250115687-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORP USA (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| WO-1994005639-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-17 | — | — | WO | disclosed |
| US-5272128-A | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0511826-A2 | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
| US-4806145-A | Herbicidal aryl triazolinones | FMC CORPORATION (US) | 1989-02-21 | — | — | US | disclosed |
| US-4743291-A | Herbicidal aryl triazolinones | FMC CORPORATION (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0199794-A4 | HERBICIDAL ARYL TRIAZOLINONES. | FMC CORP (US) | 1987-09-28 | — | — | EP | disclosed |
| EP-0199794-A1 | HERBICIDAL ARYL TRIAZOLINONES | FMC Corporation (US) | 1986-11-05 | — | — | EP | disclosed |
| WO-1986002642-A1 | HERBICIDAL ARYL TRIAZOLINONES | FMC CORPORATION (US) | 1986-05-09 | — | — | WO | disclosed |
| US-3988468-A | 7-Methoxy-6-thiatetracyclines and their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | L3MBTL1 1704/4885TP53 4741/4885ALDH1A1 4260/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | L3MBTL1 3817/4885TP53 4584/4885ALDH1A1 1864/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | L3MBTL1 1245/4885TP53 14/4885ALDH1A1 3906/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | L3MBTL1 2102/4885TP53 3755/4885ALDH1A1 4542/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | L3MBTL1 4863/4885TP53 3504/4885ALDH1A1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.